Intrinsic value of Eagle Pharmaceuticals - EGRX

Previous Close

$77.56

  Intrinsic Value

premium content

  Rating & Target

premium content

  Value-price divergence*

premium content

Previous close

$77.56

 
Intrinsic value

$551.50

 
Up/down potential

+611%

 
Rating

str. buy

 
Value-price divergence* premium content

Premium access subscription - $499/yr

please register and log in before paying

*Intrinsic value change (in %) minus stock price change (in %) in the past 12 months.

We calculate the intrinsic value of EGRX stock by summing up the current values of future distributable cash flows generated by the company and dividing the sum by the number of outstanding shares. As such, the intrinsic value calculation depends entirely on projections. The more accurate your projections of the company's performance are - the more reliable is the intrinsic value calculation result. Please make sure to check the stock valuation input data below and adjust it if necessary. The quality of the output (intrinsic valuation result) is only as good as the quality of the input. See also DISCLAIMERS.

STOCK VALUATION INPUT DATA

Revenue (in 2016), $M
Initial revenue growth rate, %
Terminal revenue growth rate, %
Revenue decline factor
Initial discount rate, %
Discount rate multiplier
Variable cost ratio, %
Fixed operating expenses, $M
Interest rate on debt, %
Effective corporate tax rate, %
Production assets / Revenue, %
Life of production assets, yrs
Working capital / Revenue, %
Revenue / Adjusted assets
Adjusted equity ratio
Cash flow adjustment, % of Revenue
Book value of equity, $M
Shares outstanding, mln
Market capitalization, $bln 1.2

 

FINANCIAL STATEMENTS FORECAST and PRESENT VALUE CALCULATION

Fiscal year
2016(a)
   2017
   2018
   2019
   2020
   2021
   2022
   2023
   2024
   2025
   2026
   2027
   2028
   2029
   2030
   2031
   2032
   2033
   2034
   2035
   2036
   2037
   2038
   2039
   2040
   2041
   2042
   2043
   2044
   2045
   2046

INCOME STATEMENT

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Revenue growth rate, %
  186.36
  60.00
  54.50
  49.55
  45.10
  41.09
  37.48
  34.23
  31.31
  28.68
  26.31
  24.18
  22.26
  20.53
  18.98
  17.58
  16.32
  15.19
  14.17
  13.26
  12.43
  11.69
  11.02
  10.42
  9.87
  9.39
  8.95
  8.55
  8.20
  7.88
  7.59
Revenue, $m
  189
  106
  163
  244
  354
  499
  687
  922
  1,210
  1,557
  1,967
  2,443
  2,986
  3,599
  4,283
  5,036
  5,858
  6,748
  7,704
  8,725
  9,809
  10,956
  12,163
  13,430
  14,756
  16,141
  17,586
  19,090
  20,655
  22,282
  23,973
Variable operating expenses, $m
 
  59
  92
  137
  199
  280
  385
  517
  679
  874
  1,103
  1,370
  1,675
  2,019
  2,403
  2,825
  3,286
  3,785
  4,322
  4,895
  5,503
  6,146
  6,823
  7,534
  8,278
  9,055
  9,866
  10,709
  11,587
  12,500
  13,449
Fixed operating expenses, $m
 
  29
  29
  30
  31
  32
  32
  33
  34
  35
  36
  37
  38
  39
  40
  41
  42
  43
  44
  45
  46
  47
  48
  49
  51
  52
  53
  55
  56
  57
  59
Total operating expenses, $m
  136
  88
  121
  167
  230
  312
  417
  550
  713
  909
  1,139
  1,407
  1,713
  2,058
  2,443
  2,866
  3,328
  3,828
  4,366
  4,940
  5,549
  6,193
  6,871
  7,583
  8,329
  9,107
  9,919
  10,764
  11,643
  12,557
  13,508
Operating income, $m
  53
  18
  42
  77
  125
  188
  269
  371
  497
  649
  828
  1,036
  1,273
  1,542
  1,841
  2,170
  2,530
  2,920
  3,338
  3,785
  4,260
  4,763
  5,291
  5,846
  6,427
  7,034
  7,667
  8,326
  9,012
  9,725
  10,466
EBITDA, $m
  55
  18
  42
  77
  125
  188
  270
  373
  499
  651
  831
  1,039
  1,278
  1,547
  1,847
  2,178
  2,539
  2,930
  3,350
  3,799
  4,275
  4,779
  5,310
  5,866
  6,449
  7,058
  7,693
  8,355
  9,043
  9,758
  10,502
Interest expense (income), $m
  0
  0
  1
  2
  3
  5
  8
  12
  16
  21
  28
  35
  44
  54
  66
  78
  92
  107
  124
  142
  161
  181
  202
  225
  248
  273
  298
  325
  353
  382
  412
Earnings before tax, $m
  53
  18
  41
  75
  121
  182
  261
  360
  481
  627
  800
  1,000
  1,229
  1,487
  1,775
  2,092
  2,438
  2,812
  3,214
  3,644
  4,100
  4,582
  5,089
  5,622
  6,179
  6,761
  7,369
  8,001
  8,658
  9,342
  10,053
Tax expense, $m
  -28
  5
  11
  20
  33
  49
  70
  97
  130
  169
  216
  270
  332
  402
  479
  565
  658
  759
  868
  984
  1,107
  1,237
  1,374
  1,518
  1,668
  1,826
  1,989
  2,160
  2,338
  2,522
  2,714
Net income, $m
  81
  13
  30
  55
  88
  133
  190
  263
  351
  458
  584
  730
  897
  1,086
  1,296
  1,527
  1,780
  2,053
  2,346
  2,660
  2,993
  3,345
  3,715
  4,104
  4,511
  4,936
  5,379
  5,841
  6,321
  6,820
  7,339

BALANCE SHEET

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cash and short-term investments, $m
  53
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Total assets, $m
  214
  74
  114
  170
  247
  348
  479
  642
  843
  1,085
  1,371
  1,702
  2,081
  2,508
  2,984
  3,509
  4,082
  4,702
  5,369
  6,080
  6,836
  7,635
  8,476
  9,359
  10,283
  11,248
  12,255
  13,303
  14,394
  15,528
  16,706
Adjusted assets (=assets-cash), $m
  161
  74
  114
  170
  247
  348
  479
  642
  843
  1,085
  1,371
  1,702
  2,081
  2,508
  2,984
  3,509
  4,082
  4,702
  5,369
  6,080
  6,836
  7,635
  8,476
  9,359
  10,283
  11,248
  12,255
  13,303
  14,394
  15,528
  16,706
Revenue / Adjusted assets
  1.174
  1.432
  1.430
  1.435
  1.433
  1.434
  1.434
  1.436
  1.435
  1.435
  1.435
  1.435
  1.435
  1.435
  1.435
  1.435
  1.435
  1.435
  1.435
  1.435
  1.435
  1.435
  1.435
  1.435
  1.435
  1.435
  1.435
  1.435
  1.435
  1.435
  1.435
Average production assets, $m
  19
  2
  2
  4
  5
  7
  10
  14
  18
  23
  30
  37
  45
  54
  64
  76
  88
  101
  116
  131
  147
  164
  182
  201
  221
  242
  264
  286
  310
  334
  360
Working capital, $m
  68
  14
  22
  33
  48
  68
  93
  125
  165
  212
  268
  332
  406
  490
  582
  685
  797
  918
  1,048
  1,187
  1,334
  1,490
  1,654
  1,826
  2,007
  2,195
  2,392
  2,596
  2,809
  3,030
  3,260
Total debt, $m
  0
  21
  52
  94
  153
  230
  329
  454
  607
  791
  1,008
  1,260
  1,549
  1,874
  2,236
  2,635
  3,071
  3,543
  4,050
  4,592
  5,167
  5,775
  6,415
  7,087
  7,790
  8,525
  9,291
  10,089
  10,919
  11,782
  12,678
Total liabilities, $m
  63
  56
  87
  129
  188
  265
  364
  489
  642
  826
  1,043
  1,295
  1,584
  1,909
  2,271
  2,670
  3,106
  3,578
  4,085
  4,627
  5,202
  5,810
  6,450
  7,122
  7,825
  8,560
  9,326
  10,124
  10,954
  11,817
  12,713
Total equity, $m
  151
  18
  27
  41
  59
  83
  114
  154
  202
  259
  328
  407
  497
  599
  713
  839
  976
  1,124
  1,283
  1,453
  1,634
  1,825
  2,026
  2,237
  2,458
  2,688
  2,929
  3,179
  3,440
  3,711
  3,993
Total liabilities and equity, $m
  214
  74
  114
  170
  247
  348
  478
  643
  844
  1,085
  1,371
  1,702
  2,081
  2,508
  2,984
  3,509
  4,082
  4,702
  5,368
  6,080
  6,836
  7,635
  8,476
  9,359
  10,283
  11,248
  12,255
  13,303
  14,394
  15,528
  16,706
Debt-to-equity ratio
  0.000
  1.190
  1.900
  2.320
  2.590
  2.760
  2.880
  2.960
  3.010
  3.050
  3.080
  3.100
  3.110
  3.130
  3.140
  3.140
  3.150
  3.150
  3.160
  3.160
  3.160
  3.160
  3.170
  3.170
  3.170
  3.170
  3.170
  3.170
  3.170
  3.170
  3.180
Adjusted equity ratio
  0.609
  0.239
  0.239
  0.239
  0.239
  0.239
  0.239
  0.239
  0.239
  0.239
  0.239
  0.239
  0.239
  0.239
  0.239
  0.239
  0.239
  0.239
  0.239
  0.239
  0.239
  0.239
  0.239
  0.239
  0.239
  0.239
  0.239
  0.239
  0.239
  0.239
  0.239

CASH FLOW

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Net income, $m
  81
  13
  30
  55
  88
  133
  190
  263
  351
  458
  584
  730
  897
  1,086
  1,296
  1,527
  1,780
  2,053
  2,346
  2,660
  2,993
  3,345
  3,715
  4,104
  4,511
  4,936
  5,379
  5,841
  6,321
  6,820
  7,339
Depreciation, amort., depletion, $m
  2
  0
  0
  0
  1
  1
  1
  1
  2
  2
  3
  4
  4
  5
  6
  8
  9
  10
  12
  13
  15
  16
  18
  20
  22
  24
  26
  29
  31
  33
  36
Funds from operations, $m
  44
  13
  31
  55
  89
  134
  192
  264
  353
  460
  587
  734
  902
  1,091
  1,302
  1,535
  1,788
  2,063
  2,358
  2,673
  3,008
  3,361
  3,733
  4,124
  4,533
  4,960
  5,405
  5,869
  6,352
  6,853
  7,375
Change in working capital, $m
  -9
  5
  8
  11
  15
  20
  25
  32
  39
  47
  56
  65
  74
  83
  93
  102
  112
  121
  130
  139
  147
  156
  164
  172
  180
  188
  196
  205
  213
  221
  230
Cash from operations, $m
  53
  9
  23
  44
  74
  114
  166
  232
  314
  413
  531
  669
  828
  1,008
  1,209
  1,432
  1,677
  1,942
  2,228
  2,534
  2,860
  3,205
  3,569
  3,952
  4,353
  4,772
  5,209
  5,665
  6,139
  6,632
  7,145
Maintenance CAPEX, $m
  0
  0
  0
  0
  0
  -1
  -1
  -1
  -1
  -2
  -2
  -3
  -4
  -4
  -5
  -6
  -8
  -9
  -10
  -12
  -13
  -15
  -16
  -18
  -20
  -22
  -24
  -26
  -29
  -31
  -33
New CAPEX, $m
  -16
  -1
  -1
  -1
  -2
  -2
  -3
  -4
  -4
  -5
  -6
  -7
  -8
  -9
  -10
  -11
  -12
  -13
  -14
  -15
  -16
  -17
  -18
  -19
  -20
  -21
  -22
  -23
  -23
  -24
  -25
Cash from investing activities, $m
  -46
  -1
  -1
  -1
  -2
  -3
  -4
  -5
  -5
  -7
  -8
  -10
  -12
  -13
  -15
  -17
  -20
  -22
  -24
  -27
  -29
  -32
  -34
  -37
  -40
  -43
  -46
  -49
  -52
  -55
  -58
Free cash flow, $m
  7
  8
  22
  43
  72
  111
  162
  228
  308
  406
  523
  659
  816
  994
  1,194
  1,414
  1,657
  1,920
  2,203
  2,507
  2,831
  3,173
  3,535
  3,914
  4,313
  4,729
  5,163
  5,616
  6,087
  6,577
  7,086
Issuance/(repayment) of debt, $m
  0
  21
  31
  43
  58
  77
  99
  125
  153
  184
  217
  252
  288
  325
  362
  399
  436
  472
  507
  542
  575
  608
  640
  672
  703
  735
  766
  798
  830
  863
  897
Issuance/(repurchase) of shares, $m
  -33
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Cash from financing (excl. dividends), $m  
  -34
  21
  31
  43
  58
  77
  99
  125
  153
  184
  217
  252
  288
  325
  362
  399
  436
  472
  507
  542
  575
  608
  640
  672
  703
  735
  766
  798
  830
  863
  897
Total cash flow (excl. dividends), $m
  -26
  29
  52
  86
  130
  188
  262
  352
  461
  590
  740
  911
  1,104
  1,319
  1,556
  1,814
  2,093
  2,392
  2,711
  3,049
  3,406
  3,781
  4,175
  4,586
  5,016
  5,463
  5,929
  6,413
  6,917
  7,440
  7,983
Retained Cash Flow (-), $m
  -61
  -7
  -10
  -13
  -18
  -24
  -31
  -39
  -48
  -58
  -68
  -79
  -91
  -102
  -114
  -125
  -137
  -148
  -159
  -170
  -181
  -191
  -201
  -211
  -221
  -231
  -241
  -251
  -261
  -271
  -282
Prev. year cash balance distribution, $m
 
  79
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Cash flow adjustment, $m
 
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Cash available for distribution, $m
 
  101
  43
  72
  112
  164
  231
  313
  413
  532
  672
  832
  1,014
  1,217
  1,442
  1,688
  1,956
  2,243
  2,551
  2,879
  3,225
  3,590
  3,974
  4,375
  4,795
  5,233
  5,688
  6,163
  6,656
  7,169
  7,701
Discount rate, %
 
  4.30
  4.52
  4.74
  4.98
  5.23
  5.49
  5.76
  6.05
  6.35
  6.67
  7.00
  7.35
  7.72
  8.11
  8.51
  8.94
  9.39
  9.86
  10.35
  10.87
  11.41
  11.98
  12.58
  13.21
  13.87
  14.56
  15.29
  16.05
  16.86
  17.70
PV of cash for distribution, $m
 
  97
  39
  63
  92
  127
  167
  211
  258
  306
  352
  395
  433
  463
  484
  496
  497
  488
  470
  443
  410
  371
  330
  287
  244
  204
  166
  132
  103
  78
  58
Current shareholders' claim on cash, %
  100
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0

Eagle Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on developing and commercializing injectable products primarily in the critical care and oncology areas in the United States. The company offers argatroban to treat heparin-induced thrombocytopenia; Ryanodex injectable suspension for the treatment of malignant hyperthermia; non-alcohol docetaxel injection, a chemotherapeutic agent for the treatment of breast, non-small cell lung, prostate, head, and neck cancers/gastric adenocarcinoma; and diclofenac-misoprostol. It develops EP-3101, a bendamustine ready to dilute (RTD) liquid; EP-3102, a bendamustine short infusion time RTD liquid for the treatment of chronic lymphocytic leukemia and indolent non-Hodgkin's lymphoma; and EP-4104, a dantrolene for the treatment of exertional heat stroke. The company also develops EP-5101 (pemetrexed) as RTD liquid, which is in pre-clinical formulation and toxicology studies to treat lung cancer and mesothelioma; and EP-6101, a bivalirudin RTU liquid formulation for the treatment of percutaneous transluminal angioplasty. Eagle Pharmaceuticals, Inc. was founded in 2007 and is headquartered in Woodcliff Lake, New Jersey.

FINANCIAL RATIOS  of  Eagle Pharmaceuticals (EGRX)

Valuation Ratios
P/E Ratio 14.7
Price to Sales 6.3
Price to Book 7.9
Price to Tangible Book
Price to Cash Flow 22.4
Price to Free Cash Flow 32.1
Growth Rates
Sales Growth Rate 186.4%
Sales - 3 Yr. Growth Rate %
EPS Growth Rate %
EPS - 3 Yr. Growth Rate %
Capital Spending Gr. Rate 700%
Cap. Spend. - 3 Yr. Gr. Rate NaN%
Financial Strength
Quick Ratio NaN
Current Ratio 0
LT Debt to Equity 0%
Total Debt to Equity 0%
Interest Coverage 0
Management Effectiveness
Return On Assets 47.8%
Ret/ On Assets - 3 Yr. Avg. 0.2%
Return On Total Capital 67.2%
Ret/ On T. Cap. - 3 Yr. Avg. -10.3%
Return On Equity 67.2%
Return On Equity - 3 Yr. Avg. -10.3%
Asset Turnover 1.1
Profitability Ratios
Gross Margin 70.9%
Gross Margin - 3 Yr. Avg. 61.7%
EBITDA Margin 29.1%
EBITDA Margin - 3 Yr. Avg. -22.1%
Operating Margin 28%
Oper. Margin - 3 Yr. Avg. -23%
Pre-Tax Margin 28%
Pre-Tax Margin - 3 Yr. Avg. -22.5%
Net Profit Margin 42.9%
Net Profit Margin - 3 Yr. Avg. -15.8%
Effective Tax Rate -52.8%
Eff/ Tax Rate - 3 Yr. Avg. -15.9%
Payout Ratio 0%

EGRX stock valuation input parameters

Revenue. Company's revenue (or sales) is always the starting point of any cash flow forecast. In the EGRX stock intrinsic value calculation we used $66 million for the last fiscal year's total revenue generated by Eagle Pharmaceuticals. The default revenue input number comes from 2016 income statement of Eagle Pharmaceuticals. You may change it if you feel that it should be adjusted for some unusual circumstances that are not expected to be repeated in the future or if you already know (from interim financial statements, for example) that this year's revenue is going to be quite different.

Revenue growth rate. Forecasted future revenue growth rate is the most important input parameter for the intrinsic value calculation. Unlike other input parameters that are reasonably expected to be in line with their historic averages or their historic trends, the revenue growth rate by and large is a wild card: nobody really knows what the company's revenue will be in the future. Of course, the level of unpredictability is different for different industries (utility companies being the most predictable and, thus, less risky).
    We use three input parameters to forecast the revenue growth rate in our EGRX stock valuation model: a) initial revenue growth rate of 60% whose default value is the revenue growth rate in the most recent quarter compared to the quarterly revenue a year ago; b) terminal revenue growth rate of 5% whose default value is chosen to be close to the average nominal (i.e. not adjusted for inflation) GDP growth rate; and c) revenue decline factor of 0.9, which stipulates that revenue growth rate in each forecasted year will be equal to the difference of the revenue growth rate in the preceding year and the terminal revenue growth rate multiplied by this revenue decline factor (with the passage of time the revenue growth rate will be approaching the terminal revenue growth rate, but not quite reaching it - though the difference could be infinitesimally small).
    At the revenue decline factor of 1, the future revenue growth rate is forecasted to be constant and equal to the initial revenue growth rate. The smaller the revenue decline factor, the faster the revenue growth rate will approach the terminal revenue growth.

Discount rate. The discount rate is used for determining the present value of future cash flows: future cash flows are "discounted" as at normal conditions (that translate into positive expected return on investment) one dollar today is worth more than the same dollar in the future. Unlike all other valuation models, we use variable discount rate, i.e. it increases for each consecutive year. This is done to account for higher risk of cash flows coming in further in the future.
    The initial discount rate of 4.3%, whose default value for EGRX is calculated based on our internal credit rating of Eagle Pharmaceuticals, is applied to the cash flow expected to be received a year from now (well, actually, to be precise, in the financial year following the base year - the last year for which we have financial statements). For each consecutive year the discount rate is multiplied by the discount rate multiplier of 1.05, e.i. each year it increases by 5%. Feel free to change this number to correspond to your level of risk assessment of Eagle Pharmaceuticals.
    By the way, it is easy to set the discount rate to be constant (this would make comparison with other valuation models easier): just set the discount rate multiplier equal to 1 and chose the magnitude of the initial discount rate to your liking.

Variable cost ratio is the ratio of variable costs (i.e. costs that fluctuate with fluctuation of the volume of production) to the revenue expressed as a percentage. In the calculation of intrinsic value of EGRX stock the variable cost ratio is equal to 56.1%.

Fixed operating expenses is just that - expenses that are not dependant on the volume of production. They are set to $28 million in the base year in the intrinsic value calculation for EGRX stock. These expenses increase with the level of inflation in subsequent years.

Interest rate on debt is the average all-in rate of interest paid by the company on its debt. It is set at 3.5% for Eagle Pharmaceuticals.

Corporate tax rate of 27% is the nominal tax rate for Eagle Pharmaceuticals. In reality, companies find ways to pay much less taxes than that or not to pay them at all.

Cash flow adjustment could be used for any adjustment the investor deems necessary. Most commonly we use this field to account for stock options-related effects in excess of what is reported on the company's income statement. The cash flow adjustment is expressed as a percentage of the revenue, and in the current valuation of the EGRX stock is equal to 0%.

Production assets are the company's assets used for manufacturing products or provision of services. In the valuation model input table they are expressed as a percentage of revenue and for EGRX are equal to 1.5%.

Life of production assets of 10 years is the average useful life of capital assets used in Eagle Pharmaceuticals operations. It is used to calculate yearly capital expenditures needed to keep these assets in good order - we call it the maintenance CAPEX.

Working capital is the difference between the company's current assets and liabilities. In the model we use the ratio of working capital to revenue, which for EGRX is equal to 13.6%. A negative number means that the company is apt at using financial resources of its suppliers and customers; a large positive number, on the other hand, means that it either provides in-kind financing to others or is not good at managing its inventories.

Book value of equity - $90 million for Eagle Pharmaceuticals - is used in calculation of the "floor" for intrinsic valuation based on the discounted cash flow (DCF) method. Even if the prospects are very bad for a company, its assets could always be sold now for their current fair market value.

Shares outstanding of 15.215 million for Eagle Pharmaceuticals is needed to calculate the intrinsic value of one share.

Market capitalization is used here only for reference purposes and as a quick check that the share price and the number of shares outstanding numbers are correct - something especially to be cognizant about at stock splits. So, the market capitalization of Eagle Pharmaceuticals at the current share price and the inputted number of shares is $1.2 billion.


Premium access subscription - $499/yr

please register and log in before paying
RELATED COMPANIES Price Int.Val. Rating
MDCO Medicines 50.53 prem.  prem.
NVS Novartis ADR 75.55 prem.  prem.
TEVA Teva Pharmaceu 33.39 prem.  prem.
CELG Celgene 123.52 prem.  prem.
PFE Pfizer 34.35 prem.  prem.
MGNX Macrogenics 19.71 prem.  prem.
MRK Merck&Co 66.47 prem.  prem.
LLY Eli Lilly 83.83 prem.  prem.
INFI Infinity Pharm 2.67 prem.  prem.

COMPANY NEWS

▶ Teva Pharma, Eagle Pharma, Depomed Among Slew Getting Price Haircuts   [May-25-17 04:10PM  Investor's Business Daily]
▶ Biotech And Pharma Industry And Stock News   [01:38PM  Investor's Business Daily]
▶ Eagle Pharmaceuticals posts 1Q profit   [May-08-17 06:56AM  Associated Press]
▶ 3 Top Biotech Stocks to Buy in 2017   [Mar-26-17 06:43AM  Motley Fool]
▶ New Strong Sell Stocks for March 6th   [Mar-06-17 10:10AM  Zacks]
▶ Eagle Pharmaceuticals posts 4Q profit   [07:04AM  Associated Press]
▶ Eagle Pharmaceuticals Pemetrexed NDA Submitted for Review   [Jan-03-17 06:50AM  Business Wire]
▶ Hedge Funds Arent Crazy About Photronics, Inc. (PLAB) Anymore   [Dec-05-16 02:04AM  at Insider Monkey]
▶ Why Eagle Pharmaceuticals Inc. Flew 38.5% Higher in August   [Sep-09-16 10:03AM  at Motley Fool]
Stock chart of EGRX Financial statements of EGRX Annual reports of EGRX
Valuation of Stocks

The paper VALUATION OF STOCKS: The Quest for Intrinsic Value provides a detailed description of our valuation model and discloses the calculation algorithm.

FREE DOWNLOAD
Follow us on:   twitter   twitter   twitter   twitter

VALUATION THEORY       ASSET ALLOCATION

About X-FIN       Site news       Privacy policy       Terms of use       FAQ

Copyright © X-FIN.com 2005-2017. All rigths reserved.